Company name: KYORIN Holdings, Inc.
Representative: Masahiro Yamashita
Representative Director,President
Securities Code: 4569, TSE 1st Sec.

Release of Eklira®Genuair®, a treatment for COPDTOKYO, Japan (May 20, 2015) ―― Kyorin Pharmaceutical Co., Ltd. (“Kyorin”) (Head office:Chiyoda-ku, Tokyo, President: Mitsutomo Miyashita), a wholly owned subsidiary of KYORIN
Holdings, Inc., released today Eklira® 400 μg Genuair® 30 inhalations, a treatment for COPD.
The product received marketing authorization from the Ministry of Health, Labour andWelfare in March 2015.
This product is a new long-acting anticholinergic inhalation medicine containing Aclidinium
Bromide as the active ingredient. It is a type of treatment for COPD that uses a novel dry
powder inhaler Genuair® with improved operability.
Eklira® Genuair ® has the following characteristics:(1) Genuair® (inhaler) is easy to operate and allows a user to confirm that inhalation has
been properly completed.
(2) Twice-daily administration of Genuair® improves day-long respiratory function. It also
helps to alleviate clinical symptoms and improve QOL, inhibiting aggravation.
(3) Genuair® rapidly decomposes into an inactive metabolite in the blood.
Kyorin has been pursuing the Franchise Customer Strategy under which it focuses its
marketing efforts on the respiratory, ear-nose-throat and urology fields. It has added Eklira®
Genuair® to the line-up of its priority area of respiratory products, and is determined tocontribute to better care for COPD patients by continuously providing up-to-date information,and ensuring the rapid dissemination of this information in the market.
We expect sales of the drug in the initial year to reach about several hundreds of million yen.
The sales of the drug is factored in consolidated forecast for the fiscal year ending March
31 2016.

■About ｢Eklira® Genuair®｣Brand name: Eklira® 400μg Genuair® 30 inhalations
Active ingredient: Aclidinium Bromide
Indication: Relief from symptoms arising from respiratory tract obstruction in
COPD patients (chronic bronchitis, pulmonary emphysema)Dosage and administration : Adults should use Eklira® Genuair® (400μg Aclidinium Bromide) 2 times
per day (1 inhalation per application).
NHI price: ¥ 3,150.90 per an inhaler (Eklira® 400μg Genuair® 30 inhalations)
Date of Drug Price Listing : May 20, 2015
Date of Launch in Japan : May 20, 2015

〈New product photo〉■About COPD
COPD (chronic obstructive pulmonary disease) is an inflammatory disease of the lung(s), and may
be caused by extended exposure to cigarette smoke and other hazardous substances. COPD gives
rise to progressive airflow obstruction, and is characterized respiratory difficulties on exertion, achronic and sustained cough, breathlessness, and sputum. In recent years, an increase in thenumber of patients has been noted around the world, including in Japan and it is estimated that there
are more than five million COPD patients in Japan1, claiming more than 16,000 lives annually, whichmakes COPD the ninth leading cause of death2. With the number of deaths caused by COPD
expected to increase sharply in the future, measures to address the impact of smoking on healthhave also been recognized as an important issue in the MHWL’s “Health Japan 21” initiative.

1 Source : Fukuchi Y, : NICE study. 2001;
2 Source : MHLW Vital Statistics 2013